# Sanjeev Sethi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sanjeev-sethi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,385 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 86 |
| i10-index | 252 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5070946918 |
| ORCID iD | 0000-0002-4536-7709 |
| Works | 449 |

## Researcher papers

Showing 12 of 27.

- [KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/kdigo-2021-clinical-practice-guideline-for-the-management-of-glomerular-diseases/)
- [Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices](https://scholariq.org/papers/revision-of-the-international-society-of-nephrology-renal-pathology-society/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference](https://scholariq.org/papers/atypical-hemolytic-uremic-syndrome-and-c3-glomerulopathy-conclusions-from-a/)
- [C3 glomerulopathy: consensus report](https://scholariq.org/papers/c3-glomerulopathy-consensus-report/)
- [Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy](https://scholariq.org/papers/rituximab-or-cyclosporine-in-the-treatment-of-membranous-nephropathy/)
- [Membranoproliferative Glomerulonephritis — A New Look at an Old Entity](https://scholariq.org/papers/membranoproliferative-glomerulonephritis-a-new-look-at-an-old-entity/)
- [The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group](https://scholariq.org/papers/the-evaluation-of-monoclonal-gammopathy-of-renal-significance-a-consensus-report/)
- [Membranous nephropathy](https://scholariq.org/papers/membranous-nephropathy/)
- [Diagnosis of monoclonal gammopathy of renal significance](https://scholariq.org/papers/diagnosis-of-monoclonal-gammopathy-of-renal-significance/)
- [C3 glomerulopathy — understanding a rare complement-driven renal disease](https://scholariq.org/papers/c3-glomerulopathy-understanding-a-rare-complement-driven-renal-disease/)
- [Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease)](https://scholariq.org/papers/membranoproliferative-glomerulonephritis-type-ii-dense-deposit-disease/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Amyloidosis: Diagnosis, Treatment, Outcomes](https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.